GlobeNewswire by notified

Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)

Share
  • Ceftobiprole met primary and secondary efficacy endpoints
  • Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022

Ad hoc announcement pursuant to Art. 53 LR

Basel, Switzerland, June 28, 2022

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB).1 Basilea is planning to submit a New Drug Application (NDA) for ceftobiprole to the U.S. Food and Drug Administration (FDA) around year end 2022. In accordance with the agreed Special Protocol Assessment (SPA), Basilea will seek approval for SAB and acute bacterial skin and skin structure infection (ABSSSI) indications based on the successfully completed ERADICATE study and the TARGET phase 3 study2, which was successfully completed in patients with ABSSSI in 2019. In addition, the company will explore the possibility for gaining approval for a third indication based on a previously performed phase 3 study in community-acquired bacterial pneumonia (CABP).3

Dr. Marc Engelhardt, Chief Medical Officer, stated: “The successful completion of the ERADICATE study is an exceptional achievement. ERADICATE is the largest double-blinded randomized study conducted of a new antibiotic treatment in SAB. The positive results underline the potent activity of ceftobiprole for treating serious bacterial infections. Achieving this important milestone enables us to proceed with a regulatory filing. Ceftobiprole would be the first beta-lactam antibiotic approved in the U.S. for the treatment of SAB caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus, addressing important medical needs.”

Thomas Holland, M.D., Associate Professor of Medicine at Duke University School of Medicine and chair of the ERADICATE Data Review Committee said: “This is a landmark study in an area with a high need to provide new treatments to patients. Complicated Staphylococcus aureus bloodstream infections are common and associated with high morbidity and significant mortality and available antibiotic treatment options are limited, especially when methicillin-resistant Staphylococcus aureus is involved. The ERADICATE study provides strong support for the efficacy and safety of ceftobiprole in complicated SAB. This large phase 3 study included patients with a wide spectrum of underlying complications, underscoring its broad applicability to routine clinical practice.”

The ERADICATE study enrolled 390 patients with complicated SAB, including right-sided endocarditis. Ceftobiprole met the pre-specified efficacy objective of overall success in the modified intent-to-treat (mITT) population at 70 days after randomization, assessed by an independent Data Review Committee, within the pre-specified non-inferiority margin of 15% compared to daptomycin, with or without aztreonam.

The overall success rate was 69.8% with ceftobiprole compared to 68.7% with daptomycin, with or without aztreonam. The statistically adjusted difference between ceftobiprole and the comparator group was 2.0% (95% confidence interval: -7.1% to 11.1%). Initial subgroup analyses showed no significant differences between the two treatment groups.

Ceftobiprole was well tolerated and the observed safety profile was consistent with previous phase 3 studies and the post-marketing experience with ceftobiprole. In the ERADICATE study the overall rate of adverse events was similar between the two treatment groups. As expected, gastrointestinal side effects were more frequent with ceftobiprole.

Basilea plans to submit the full data from this study for presentation at an upcoming scientific conference.

Ceftobiprole was designated a Qualified Infectious Disease Product (QIDP) by the FDA for SAB, ABSSSI and CABP. Therefore, if approved, ceftobiprole would be eligible to receive ten years of market exclusivity in the U.S. from the date of approval. The U.S. represents the most important commercial market for ceftobiprole, with Basilea’s estimate ranging from 80 to 90 percent of the global potential.

Basilea’s ceftobiprole phase 3 program is funded in part (up to USD 134.2 million, which is approximately 70% of the total potential program costs) with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C.

Conference call and webcast

Basilea Pharmaceutica Ltd. will host a conference call and webcast today, Tuesday, June 28, 2022, at 4 p.m. (CEST), to discuss the ERADICATE topline results.

Via audio webcast with presentation

The live audio webcast of the presentation of the results can be followed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=28DAz4AN. Please note that there is no function to ask questions via webcast. For questions, please additionally dial in via phone (see below).

Via phone

To listen by phone and ask questions, please use the dial-in details below. To ensure prompt access, please call approximately five minutes prior to the scheduled start of the call.

+41 (0) 58 310 5000(Europe and RoW)
+1 (1) 866 291 4166(USA)
+44 (0) 207 107 0613(U.K.)

Replay

The webcast, along with the presentation will be available online shortly after the event and accessible for three months.

About ceftobiprole

Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp.4 The brand is currently approved and marketed as Zevtera and Mabelio in a number of countries in Europe and beyond. Basilea has entered into license and distribution agreements in Europe, Eurasian countries, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) regions.

About the ceftobiprole phase 3 program

The ERADICATE study1 was a randomized, double-blind, multicenter phase 3 study, which enrolled 390 patients with SAB and compared the safety and efficacy of intravenous ceftobiprole medocaril with intravenous daptomycin plus optional intravenous aztreonam for coverage of Gram-negative pathogens. Patients were enrolled at more than 50 study centers in Eastern and Central Europe, Israel, Latin America, the Republic of South Africa, and the U.S.

The TARGET study2 was a randomized, double-blind, multicenter phase 3 study, which enrolled 679 patients with ABSSSI and compared the safety and efficacy of intravenous ceftobiprole medocaril with intravenous vancomycin plus intravenous aztreonam. The study was conducted at more than 30 clinical centers in the U.S. and Europe.

The two phase 3 studies were conducted under Special Protocol Assessment (SPA) agreements with the U.S. FDA.

About Staphylococcus aureus bacteremia (SAB)

Staphylococcus aureus bacteremia is a leading cause of bloodstream infections, responsible for a broad variety of complications and has been associated with significant morbidity and a mortality of 20 to 40%.5, 6 Several studies have demonstrated that MRSA bacteremia is associated with a significantly higher mortality rate compared with MSSA bacteremia.7, 8 Infections of the inner lining of the heart or heart valves (infective endocarditis) and bone infections (osteomyelitis) are common complications of SAB.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This ad hoc announcement can be downloaded from www.basilea.com.

References

  1. ERADICATE: ClinicalTrials.gov identifier NCT03138733
    K. Hamed, M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiology. 2020 (1), 35-48
  2. TARGET: ClinicalTrials.gov identifier NCT03137173
    J. S. Overcash, C. Kim, R. Keech R et al. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clinical Infectious Diseases 2021 (73), e1507-e1517
  3. S. C. Nicholson, T. Welte, T. M. File Jr. et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalization, International Journal of Antimicrobial Agents 2021 (39), 240-246
  4. Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: June 27, 2022]
  5. A. G. Jensen, C. H. Wachmann, F. Espersen et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Archives of Internal Medicine 2002 (162), 25-32
  6. J.-L. Wang, S.-Y. Chen, J.-T. Wang et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clinical Infectious Diseases 2008 (46), 799-806
  7. S. I. Blot, K. H. Vandewoude, E. A. Hoste et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Archives of Internal Medicine 2002 (162), 2229-2235
  8. S. E. Cosgrove, G. Sakoulas, E. N. Perencevich et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clinical Infectious Diseases 2003 (36), 53-59

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Expereo acquires Breeze Networks, further enhancing its SD-WAN/SASE practice and presence in the UK market15.8.2022 08:00:00 CEST | Press release

AMSTERDAM, Aug. 15, 2022 (GLOBE NEWSWIRE) -- The world’s leading provider of managed network solutions, Expereo, has announced the acquisition of Breeze Networks, a managed service provider of SD-WAN/SASE technologies. The acquisition fuels Expereo’s growth trajectory, further enhancing its SD-WAN/SASE practice, building on its expanding range of services to manage SD-WAN solutions at scale to partners and multinational enterprise customers across the globe. This latest acquisition solidifies Expereo’s ambition to complement its managed network solutions with world-class advisory practice providing guidance to organizations on their global transformation to software-defined and internet-based networking. With the full support of majority investor Vitruvian Partners and minority investor Apax Partners SAS, Expereo intends to continue its acquisition strategy. Breeze Networks is a managed service provider of cloud-based (SD-WAN) network connectivity and security solutions for enterprises

DNO Releases 2021 Corporate Social Responsibility Report15.8.2022 08:00:00 CEST | Press release

Oslo, 15 August 2022 – DNO ASA, the Norwegian oil and gas operator, today released its 2021 Corporate Social Responsibility Report. The report is attached as a downloadable file and is also available on the Company's website www.dno.no. – For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2021 CSR report

Sampo plc’s share buybacks 12/08/202215.8.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 15/08/2022 at 08:30 am Sampo plc’s share buybacks 12/08/2022 On 12/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,42245.06AQEU29,72844.98CEUX9,01645.09TQEX76,83445.02XHELTOTAL130,00045.02 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 6,194,495 Sampo A shares representing 1.16 per cent of the total number of shares in Sampo plc. Details of ea

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer15.8.2022 07:15:00 CEST | Press release

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1 Findings will be presented at an upcoming medical meeting Novartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancer Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo1. No unexpected safety signals were observed.1 Findings from the trial will be presented at an upcoming medical meeting. “We made an investment in the CANOPY program based on signals of reduced lung cancer incidence and mortality observed in the CANTOS s

DNO Shares Traded Ex-Dividend15.8.2022 07:00:00 CEST | Press release

Oslo, 15 August 2022 – DNO ASA, the Norwegian oil and gas operator, today announced that the Company’s shares will be traded ex-dividend effective 15 August 2022. A dividend payment of NOK 0.25 per share will be made on or about 23 August 2022 to all shareholders of record as of 16 August 2022. – For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and section 4.2.5.3 of Euronext Oslo Rulebook II.